Frequency distribution of relapses and retreatment after relapses of the 45 patients.
| Followup Month | Continued in Remission n (%) | Relapses, n (%) | Patient Who Relapsed | Core Study | Treatment After Relapse |
|---|---|---|---|---|---|
| 0 | 45 (100) | 0 (0) | |||
| 1 | 43 (96) | 2 (4) | 1 | AMBITION | MTX+CLQ+DFZ |
| 2 | AMBITION | ADA+MTX | |||
| 2 | 40 (89) | 3 (7) | 3 | OPTION | TCZ+MTX |
| 4 | OPTION | MTX↑ | |||
| 5 | RADIATE | RTX+MTX | |||
| 3 | 31 (69) | 9 (20) | 6 | ROSE | MTX↑ |
| 7 | OPTION | TCZ+MTX | |||
| 8 | OPTION | MTX+CLQ | |||
| 9 | OPTION | ETA+MTX | |||
| 10 | OPTION | ETA+MTX | |||
| 11 | OPTION | ETA+MTX | |||
| 12 | AMBITION | MTX↑ | |||
| 13 | RADIATE | TCZ+MTX | |||
| 14 | RADIATE | RTX+MTX | |||
| 5 | 24 (53) | 7 (16) | 15 | ROSE | MTX↑ |
| 16 | ROSE | MTX+CLQ+PDN | |||
| 17 | OPTION | MTX↑ | |||
| 18 | AMBITION | MTX+CLQ+PDN+SFZ | |||
| 19 | AMBITION | MTX↑ | |||
| 20 | AMBITION | MTX↑ | |||
| 21 | AMBITION | TCZ+MTX | |||
| 7 | 23 (51) | 1 (2) | 22 | AMBITION | MTX↑ |
| 9 | 22 (49) | 1 (2) | 23 | AMBITION | MTX↑ |
| 10 | 20 (44) | 2 (4) | 24 | AMBITION | MTX+CLQ+SFZ |
| 25 | AMBITION | RTX+MTX | |||
| 12 | 20 (44) | 0 (0) | — | — | — |
| Total | 20 (44) | 25 (56) |
MTX: methotrexate; MTX↑: methotrexate dose increase; CLQ: chloroquine; DFZ: deflazacort; ADA: adalimumab; TCZ: tocilizumab; RTX: rituximab; ETA: etanercept; PDN: prednisone; SFZ: sulfasalazine.